908 Devices has announced a joint innovation partnership with Hangzhou Just Biotherapeutics (HJB), an integrated design company focused on technologies that will accelerate development of biotherapeutics and reduce manufacturing costs to make medicines more readily available in the global marketplace.
ZipChip is a plug-and-play separations platform that optimizes mass spectrometry analysis.
HJB partners with innovative technology developers that can aid in their like-minded goal of developing meaningful therapeutics at lower cost to dramatically expand global access to vital medicines in underserved markets.
HJB has recently launched a world-class pharmaceutical development facility in Hangzhou, Zhejiang where only leading-edge technologies — including the 908 Devices ZipChip® platform — will be integrated into their on-site processes.
HJB co-founder and CEO Jonathan Zhao said: “We are searching for analytical tools that can provide higher quality data, get us to results faster, and can be leveraged to reduce overall manufacturing costs.
“The ZipChip platform is a prime example as it streamlines internal processes and gives us access to data we haven’t been able to get before. We believe it will be very impactful to our business.”
908 Devices CEO and co-founder Kevin Knopp said: “We are truly excited about our partnership with HJB and the role 908 Devices can play in their overarching mission to develop vital, accessible medicines.
“HJB is extremely innovative and has a clear vision for how ZipChip can give them the edge they need in all stages of biopharma development and production.”
908 Devices also announced the availability of their ZipChip platform in China.